Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital

February 28, 2022 8:49 AM EST

BMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining a Market Perform rating following results.

The analyst commented, "4Q beat although rev. was preannounced, but margin improvement coming through and should accelerate following... More